. Author manuscript; available in PMC: 2014 Aug 1.

Published in final edited form as: J Mol Endocrinol. 2014 Mar 6;52(2):181–189. doi: 10.1530/JME-13-0266

Table 3.

Clinicopathological characteristics and expression of miR-150 and miR-23b. Although there were initially 27 PD and oPD, the assay for miR-150 failed in one sample and for miR-23b in 4 samples, reflecting the difficulties with downregulated markers.

MiRNA (fold change)		miR-150 <0.2	miR-150 ≥0.2	P-value
Age (years)		68.8±9.7	67.1±11.2	0.774
pT	pT 1–2	1	2	0.446
pT	pT 3–4	14	9	0.446
gender	male	7	3	0.082
gender	female	8	8	0.082
MiRNA (fold change)		miR-23b <0.5	miR-23b ≥0.5
Age (years)		69.6±9.6	64.7±12.5	0.615
pT	pT 1–2	2	1	0.584
pT	pT 3–4	12	8	0.584
gender	male	6	2	0.024
gender	female	8	7	0.024